http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++enGene+Therapeutics+Inc.++For%3A+Jul+16++Filed+by%3A+Richton+Kathleen+P./26801653.html si-local-file:///var/storage/secattach/20260722/26801653.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++enGene+Therapeutics+Inc.++For%3A+Jul+16++Filed+by%3A+Richton+Kathleen+P./26801653.html Wed, 22 Jul 2026 16:06:00 -0400 ENGN O.61395639 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++enGene+Therapeutics+Inc.++For%3A+Jul+16++Filed+by%3A+Richton+Kathleen+P./26801653.html si-local-file:///var/storage/secattach/20260722/26801653.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++enGene+Therapeutics+Inc.++For%3A+Jul+16++Filed+by%3A+Richton+Kathleen+P./26801653.html Wed, 22 Jul 2026 16:06:00 -0400 ENGN O.61395639 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++enGene+Therapeutics+Inc.++For%3A+Jul+16++Filed+by%3A+Chinoporos+Constantine/26801668.html si-local-file:///var/storage/secattach/20260722/26801668.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++enGene+Therapeutics+Inc.++For%3A+Jul+16++Filed+by%3A+Chinoporos+Constantine/26801668.html Wed, 22 Jul 2026 16:06:00 -0400 ENGN O.61395639 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++enGene+Therapeutics+Inc.++For%3A+Jul+16++Filed+by%3A+Chinoporos+Constantine/26801668.html si-local-file:///var/storage/secattach/20260722/26801668.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++enGene+Therapeutics+Inc.++For%3A+Jul+16++Filed+by%3A+Chinoporos+Constantine/26801668.html Wed, 22 Jul 2026 16:06:00 -0400 ENGN O.61395639 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++enGene+Therapeutics+Inc.+++++++++++++++Filed+by%3A+ACORN+BIOVENTURES%2C+L.P./26799294.html si-local-file:///var/storage/secattach/20260722/26799294.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++enGene+Therapeutics+Inc.+++++++++++++++Filed+by%3A+ACORN+BIOVENTURES%2C+L.P./26799294.html Wed, 22 Jul 2026 09:14:00 -0400 ENGN O.61395639 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++enGene+Therapeutics+Inc.+++++++++++++++Filed+by%3A+ACORN+BIOVENTURES%2C+L.P./26799294.html si-local-file:///var/storage/secattach/20260722/26799294.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++enGene+Therapeutics+Inc.+++++++++++++++Filed+by%3A+ACORN+BIOVENTURES%2C+L.P./26799294.html Wed, 22 Jul 2026 09:14:00 -0400 ENGN O.61395639 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++enGene+Therapeutics+Inc.++For%3A+Jul+17/26784366.html si-local-file:///var/storage/secattach/20260717/26784366.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++enGene+Therapeutics+Inc.++For%3A+Jul+17/26784366.html Fri, 17 Jul 2026 16:06:00 -0400 ENGN O.61395639 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++enGene+Therapeutics+Inc.++For%3A+Jul+17/26784366.html si-local-file:///var/storage/secattach/20260717/26784366.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++enGene+Therapeutics+Inc.++For%3A+Jul+17/26784366.html Fri, 17 Jul 2026 16:06:00 -0400 ENGN O.61395639 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++enGene+Therapeutics+Inc.++For%3A+Jul+15/26776991.html si-local-file:///var/storage/secattach/20260716/26776991.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++enGene+Therapeutics+Inc.++For%3A+Jul+15/26776991.html Thu, 16 Jul 2026 08:07:00 -0400 ENGN O.61395639 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++enGene+Therapeutics+Inc.++For%3A+Jul+15/26776991.html si-local-file:///var/storage/secattach/20260716/26776991.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++enGene+Therapeutics+Inc.++For%3A+Jul+15/26776991.html Thu, 16 Jul 2026 08:07:00 -0400 ENGN O.61395639 http://www.streetinsider.com/Board+Changes/enGene+names+new+board+chairman+ahead+of+planned+BLA+filing/26776957.html <p>enGene Therapeutics Inc. (Nasdaq: ENGN) announced changes to its board of directors, with Michael Heffernan assuming the role of chairman and Dr. Richard Glickman stepping down after more than 14 years in the position.</p><p>Heffernan has served on enGene's board since July 2025. He is the founder of Collegium Pharmaceutical and has previously held leadership roles at Onset Dermatologics, Clinical Studies Ltd., and Eli Lilly and Company. He currently serves as chairman at NMD Pharma, Avalo Therapeutics, and AAVantgarde Bio, and as a board member at Biohaven, Trevi Therapeutics, and K36 Therapeutics.</p><p>The board changes come as enGene plans a pre-Biologics License http://www.streetinsider.com/Board+Changes/enGene+names+new+board+chairman+ahead+of+planned+BLA+filing/26776957.html Thu, 16 Jul 2026 08:01:17 -0400 ENGN http://www.streetinsider.com/Corporate+News/enGene+names+new+board+chairman+ahead+of+planned+BLA+filing/26776957.html <p>enGene Therapeutics Inc. (Nasdaq: ENGN) announced changes to its board of directors, with Michael Heffernan assuming the role of chairman and Dr. Richard Glickman stepping down after more than 14 years in the position.</p><p>Heffernan has served on enGene's board since July 2025. He is the founder of Collegium Pharmaceutical and has previously held leadership roles at Onset Dermatologics, Clinical Studies Ltd., and Eli Lilly and Company. He currently serves as chairman at NMD Pharma, Avalo Therapeutics, and AAVantgarde Bio, and as a board member at Biohaven, Trevi Therapeutics, and K36 Therapeutics.</p><p>The board changes come as enGene plans a pre-Biologics License http://www.streetinsider.com/Corporate+News/enGene+names+new+board+chairman+ahead+of+planned+BLA+filing/26776957.html Thu, 16 Jul 2026 08:01:17 -0400 ENGN http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Press+Releases/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html <p class="bwalignc"> <i>Michael Heffernan assumes the role of Chairman of the Board</i> </p><p class="bwalignc"> <i>Dr. Richard Glickman to step down</i> </p><p class="bwalignc"> <i>Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026</i> </p><p class="bwalignc"> <i>Initiation of BLA submission for detalimogene planned for 2H 2026</i> </p><p class="bwalignc"> <i>Potential FDA approval of detalimogene in 2027</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, http://www.streetinsider.com/Business+Wire/enGene+Focuses+Board+to+Support+Planned+Upcoming+Regulatory+and+Commercial+Milestones/26776884.html Thu, 16 Jul 2026 08:00:00 -0400 A.06822034 A.50216941 A.50216997 ENGN O.03094572 O.20026344 O.54747943 O.61395639